NO SKIPPED BEATZ: A PRACTICAL REVIEW OF THE ANTI-ARRHYTHMIX
|
|
- Clement Arnold
- 5 years ago
- Views:
Transcription
1 NO SKIPPED BEATZ: A PRACTICAL REVIEW OF THE ANTI-ARRHYTHMIX feat. Lance Ray, Pharm.D., BCPS ADJUNCT ASSOCIATE PROFESSOR OF PHARMACOTHERAPY UNIVERSITY OF NORTH TEXAS COLLEGE OF PHARMACY
2 Get Rhythm Learning Objectives: (Pharmacists) 1. Summarize the pathophysiology of arrhythmias and describe how different antiarrhythmic drug classes aim to control these rhythm disturbances 2. Describe various acute and long-term evidence-based approaches to therapy for atrial fibrillation 3. Identify various treatment strategies for other common supraventricular-, ventricular-, and brady-arrhythmias Learning Objectives: (Technicians) 1. Identify the common uses for anti-arrhythmic drugs while reviewing basic arrhythmia pathophysiology 2. Describe the concept of rate versus rhythm control in atrial fibrillation 3. Identify scenarios when electrical cardioversion are indicated for normal rhythm restoration ACPE description: We will briefly review the pathophysiology of common arrhythmias and how various agents aim to control them both in the acute and long-term setting. Landmark-trials and adverse effects will be profiled for common drugs.
3 Review Nerve conduction SA node - Atrial pacemaker AV node - Speed bump [correct] pathway to conduct to ventricles Muscle contraction unique cells (automaticity) Refractory period Important for impulse termination if absent vicious loop(s)
4 Why do arrhythmias occur? Ion channel conduction disturbance Myocardial infarction (MI) Ischemia myocardial scarring Cardiovascular disease Ventricular hypertrophy Hypertension RAAS activation Genetic mutation/ polymorphism Increased sympathetic tone Hyperthyroidism Exercise Metabolic disturbances Diabetes Obesity Oxidative stress Age Smoking Alcohol use Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e. 2011
5 Most common type of arrhythmia Atrial Fibrillation by far
6 A Epidemiology of AF Prevalence: % of population 4% of population over age 60 (Increases with age) Comorbidities: CHF (increases with severity) 4% AF in NYHA class I 50% AF in NYHA class IV Go AS et al. Heart Disease and Stroke statistics 2013 update. Report from AHA. Circulation 2013;127:e6-e245 Lloyd-Jones DM, et al. Framingham Heart Study. Circulation. Aug ;110(9):1042-6
7 Projected AF incidence assuming no increase in age-adjusted AF incidence assuming continued increase in incidence rates Circulation vol. 114 no
8 Concept of Re-entry Indefinite loop of impulse conduction? Impulse travels too quick or? extra impulse generated or? Shortened refractory period Can occur anywhere in the cardiac conduction system Atrium AFib (multiple foci), Atrial flutter (one focus) Ventricle VT (usually triggered by a PVC) AV node AVNRT PSVT
9 AF begets AF - Electrical remodeling occurs - Important to treat promptly
10 Re-entry We need to either - SLOW CONDUCTION Velocity (to a point that impulse dies out) or - PROLONG REFRACTORINESS (to block impulse) All anti-arrhythmic drugs do one or both of these Pharmacotherapy: A Pathophysiologic Approach. 9 th ed.
11 Vaughan-Williams Class I Slows conduction II III Prolongs refractory period IV
12 Arrhythmias Asymptomatic Incidental finding Life-threatening Emergency Anti-arrhythmic drugs can be pro-arrhythmic
13 Clinical History of Anti-arrhythmics 1950s lidocaine, quinidine 1980s surge of new anti-arrhythmic drugs (AAD) 1990s and on general decline in use Declined use for two reasons: 1. Toxicities with AADs (drug-interactions, proarrythmic!) 2. Technical advances in non-pharmacological therapy Catheter ablation of re-entry loops (Afib, Aflutter) Implantable cardioverter-defibrillators (ICD) (VT/VF)
14 Classification of Antiarrhythmics Vaughn Williams Most frequently used classification system Limitations multiple mechanisms may exist for a drug/class Does not incorporate clinical indication (AF, VT) makes difficult to summarize classes Class Pharmacologic MOA Clinical MOA notes I Na + channel block Rhythm Class Ia, Ib, Ic II β-block Rate All B-blockers III K + channel block Rhythm Multiple MOAs IV Ca ++ channel block Rate Non-DHP CCB V Digoxin / adenosine ~rate / other Drugs not related
15 Class I AADs Ia Ib Ic Quinidine (PO) Disopryamide (PO) Procainamide (IV) Lidocaine (IV) Mexilitine (PO) Flecainide (PO) Propafenone (PO) CCV = chemical cardioversion SR = sinus rythm Clinical use/comments: - Supraventricular and ventricular arrhythmias - Little use of oral agents - Procainamide for immediate AF CCV - Limited to life-threatening ventricular arrhythmias - Most potent Na + blocking effects - First-line agents within Class I for Maintenance of SR for AF/AFlutter - Or life-threatening refractory ventricular arrhythmias AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76 Pharmacotherapy: A Pathophysiologic Approach. 9 th ed.
16 Class I ADRs Ia Ib Ic Quinidine (PO) Procainamide (IV) Disopryamide (PO) Lidocaine (IV) Mexilitine (PO) Flecainide (PO) Propafenone (PO) Major Individual ADRs Hemolytic anemia, GI upset Hypotension Anti-cholinergic symptoms (Vagolytic effect = HR) Acute liver injury, Bronchospasm, AV block Class effect QTc, TdP, Heart failure, ventricular arrhythmias Dizziness, sedation, confusion, blurred vision Dizziness, Heart failure, Ventricular arrhythmia Contraindicated in SHD CYP 2D6 substrates SDH = Structural Heart Disease TdP = torsades de pointes AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76 Pharmacotherapy: A Pathophysiologic Approach. 9 th ed.
17 Summary of Class I agents Use has greatly declined No new FDA approvals for class in 20 years Many patients do not tolerate and must discontinue therapy ( 20 30%) Most pro-arrhythmic of all Vaughan Williams Classes (limits use to younger/healthier patients)
18 Class III Amiodarone Sotalol Clinical use Most (?best) evidence in AF rhythm control IV is first line agent in acute VT/VF Both utilized in supraventricular OR ventricular arrhythmias Dronedarone Ibutilide (IV) Dofetilide (PO) Only approved for AFib Used for acute chemical cardioversion AF/Atrial flutter sinus rhythm Long term maintenance of sinus rythym
19 Amiodarone is unique most commonly used AAD Displays actions of ALL Classes (I, II, III and IV) Predominantly class III Non-selective β-blocking, Ca ++ blocking effects Low-pro-arrhythmic effect IV therapy (acute indications for ACLS VT / VF) slow onset with PO: loading regimen Long half-life 60 days Adverse effects Drug interactions Inhibits MOST CYPs
20 Amiodarone - ADRs Associated with chronic therapy cumulative doses Close monitoring Adverse Effect Monitoring Treatment Hyper/hypothyroidism (2 30%) Pulmonary fibrosis ( risk w/ cumulative dose) Routine thyroid function tests Annual CXR Thyroid/anti-thyroid supplement or DC DC therapy LFT abnormalities (15 25%) transient Routine LFTs Lower dose/dc Optic neuropathy (1 2%) Routine eye exams DC therapy Photosensitivity (25 75%) Use sun-block Preventative Blue-gray skin discoloration (1-3%) DC therapy TdP (<1%), bradycardia, hypotension Routine ECGs Dose adjustment Q J Med 2011; 104: Am J Med ;706 Pharmacotherapy: A Pathophysiologic Approach. 9 th ed.
21 Amiodarone Drug-Drug Interactions P-glycoprotein (P-gp) inhibitor Can increase digoxin levels by 2x Empirically reduce digoxin by 50% Inhibitor of CYP2C9, 2C19, 3A4, 2D6 warfarin (can elevate levels 0 200%) Depends on amiodarone maintenance dose Empirically reduce warfarin dose by ~30% 400mg QD 40% 300mg QD 35% 200mg QD 30% 100mg QD 25% Chest. 2002;121(1):19-23
22 Dronedarone: Amiodarone without Iodine Dronedarone (Multaq ) (FDA approved in 2009) paroxysmal or persistent AF Similar properties (all 4 class effects) Non-iodinated Less organ toxicity than amiodarone Methylsulfonyl addition less lipophilic Only PO available Increased mortality in heart failure patients vs placebo Black Box Warning: NHYA Class IV or II-III w/ recent decompensation ANDROMEDA Study - NEJM 2008; 358: Dronedarone vs amiodarone Dronedarone less effective for rhythm control in AF than amiodarone Less adverse effects and less all-cause mortality than amiodarone $$$ J Am Coll Cardiol. 2009;54(12):
23 Dronedarone CYP450 2D6 and 3A4 inhibitor Citalopram and TCAs are contraindicated Many other drugs: use caution P-gp inhibitor increases levels of digoxin, rivaroxaban, dabigatran
24 Sotalol Non-selective B-Blocker with K + -blocking properties (Class II and III) Clinical use: Maintain sinus rhythm in AF As effective as Class I agents but less toxicity In general less effective than amiodarone but also less toxicity As effective as amiodarone in patients with ischemic heart disease/cad Avoid in HF Niche use long-term rhythm control pts w underlying CAD Clinical use: recurrent or sustained VT SAFE-T Investigators. N Engl J Med 2005;352: AFFIRM Investigators. N Eng J Med 2002;347: Pharmacotherapy: A Pathophysiologic Approach. 9 th ed.
25 Sotalol ADRs: Generally well-tolerated (<15% discontinue due to ADRs) Fatigue, bradycardia, dyspnea, dizziness, Possibility of TdP, initiation in-hospital preferred Renally eliminated Must be renally adjusted No CYP450-mediated drug interactions Black Box warning - QTc Betapace AF renal adjustments CrCl >60 ml/min: Give q12hr CrCl ml/min: Give once daily CrCl <40 ml/min: Contraindicated Formulations of sotalol Can be used for ventricular tachycardias Betapace AF (specifically indicated for AF) Same drug better labeling (?)
26 AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76 Pharmacotherapy: A Pathophysiologic Approach. 9 th ed. Less commonly used Class III Ibutilide (Corvert ) - IV One-time dose for immediate chemical cardioversion (CCV) Dofetilide (Tikosyn ) PO Long-term therapy in specific patients Must be initiated in hospital (minimum 3 days) Highest risk of TdP since pure K+ channel blockade Eliminate other risk factors for TdP before therapy Correct low serum [Mg++] and [K+] ensure baseline QTc < 440 ms
27 Dofetilide Black Box warning: To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education. Safe for patients with structural heart disease DIAMOND Study 59% conversion rate vs 34% in placebo 79% kept in SR at one year vs 42% placebo TdP occurrence of up to 3% (majority in first 3 days) 125mg 500mg PO q12h Titration algorithm Circulation. 2001; 104: Tikosyn package insert. 3/2015
28 Dofetilide initiation algorithm Determine baseline QTc ( 440 ms) Eliminate drug interactions Replace K and Mg Estimate CrCl from Tikosyn REMS Treatment Guidleline
29 Class II and IV (rate control agents) Drugs do nothing to underlying arrhythmia Most AF symptoms associated with RVR Rapid Ventricular Response Block AV node = control ventricular response = RATE CONTROL Patient is still technically in Afib Sinus pacemaker (SA node) Atrio-ventricular node (AV node) - Delay switch to allow ventricular filling speed bump - Only proper nerve conduction pathway to ventricle
30 Class II Beta-Blockers Decrease adrenergic tone primarily in SA/AV nodes conduction velocity, refractoriness, automaticity Clinical use: Slows ventricular response to Afib (RATE control) Additional properties Possible effects on electrical conduction Mortality benefits - post-mi and CHF
31 Acute rate control Which beta-blockers? virtually any Esmolol or Metoprolol available IV Chronic rate control (PO) Metoprolol Carvedilol (with HF) Atenolol Propranolol (non-selective and lipophilic) toxicity Most commonly used
32 Class IV Verapamil and Diltiazem Specifically affect calcium channels in SA and AV node Decrease heart rate rate control in AF and Atrial flutter
33 Class V - Digoxin Rate control via multiple mechanisms Narrow therapeutic index ( ng/ml) toxicity > 2.4 ng/ml Clinical fit: little use for rate control (third line agent) More effective, more rapid and less toxic drugs available Can be useful in patients with AF and HF no increased survival data for either AF or CHF indication TREAT-AF Study (2014) Retrospective cohort of newly diagnosed AF patients in VA system (n = 122,465) Digoxin use associated with 26% higher mortality rate (p < 0.001) at ~ 5 years Unfavorable kinetics J Am Coll Cardiol. 2014;64: Pharmacotherapy: A Pathophysiologic Approach. 9 th ed. AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
34 1. Circulation. 2015;132: , Take away points I rhythm control - rarely used anymore II rate control in AFib (better evidence than class IV) 1 III rhythm control amiodarone most commonly used, beware of toxicities IV rate control in AFib V digoxin rate control little utility No magic bullet Class I and III (rhythm control) falling out of fashion 1. Better therapies exist Conversion of rhythm with DCC Catheter ablation 2. Long term control of Rate > Rhythm [AFFIRM Trial]
35 TREATMENT OF ATRIAL FIBRILLATION
36 General Approach to AF Acute treatment - Symptom control - Decrease ventricular rate Consider restoring sinus rhythm (cardioversion) - Risk vs benefit Prevent long-term complications - Thromboembolism - Recurrence of AF
37 Acute management Symptomatic AF Hemodynamically unstable Medical emergency electrical cardioversion (DCC) Stable or advanced age/comorbidities Rate control Preferred in stable AF patients AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
38 Methods of Cardioversion Goal: to restore sinus rhythm Electrical shock Direct Current Cardioversion (DCC) Synchronized cardioversion Pharmacological (Chemical) Cardioversion Class I or Class III anti-arrhythmic New onset AF: spontaneous conversion rate ~60% at 24 hours (still cardiovert if unstable) Musco, S et al. Med Clin N Am. 92 (2008)
39 acute management of AF Initial rate control Intravenous class II or IV agent diltiazem (not with decomp CHF) metoprolol (not in asthma exac) IV Digoxin (second-line) slow onset, full effect at hours Initial Goal: HR < 100 Amiodarone if contraindications to above cardioversion can happen January et al. AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
40 After initial rate / symptom control Cardioversion? Usually avoid cardioversion if: advanced age (> 65) multiple comorbidities recurrent AF (risks/challenges of maintaining sinus rhythm outweigh benefit) Vast majority of patients! January et al. AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
41 Cardioversion Electrical success rates (~80 90 %) Requires procedural sedation (anesthesia) Pharmacological Lower rates of cardioversion (~60 70% among most agents) Direct current cardioversion (DCC) Class I or III anti-arrhythmic 1. January et al. AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76 Musco, S et al. Med Clin N Am. 92 (2008)
42 Rhythm Control Strategy Overview Rate control Ventricular rate, leave in AF Symptom control Beta Blocker Calcium Channel Blocker Digoxin Rhythm control Restore and maintain sinus rhythm Restore Electrical cardioversion Pharmacological cardioversion Maintain Pharmacologic Maintenance Class I or III anti-arrhythmic Catheter ablation
43 Pharmacologic Cardioversion (in ED and typically under direct cardiologist care) IV therapy agents Ibutilide Risk of TdP; pretreat with IV Magnesium sulfate Procainamide Hypotension, long infusion time Amiodarone Second line for pharmacologic conversion IV therapy usually converts within minutes to hours Oral therapy agents flecainide, propafenone, dofetilide Several contraindications AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
44 So we ve successfully cardioverted But.at one year, AF recurrence is ~75 % if left untreated Even if treated, long-term rhythm control strategy reduces to 30 50% at 1 year! So we could forget about cardioversion and just alleviate symptoms by slowing heart rate Either one is be acceptable - highly depends on circumstance Lafuente-Lafuente C, et al. Arch Intern Med. 2006;166:
45 Long-term therapy RATE CONTROL OR RHYTHM CONTROL? LANDMARK TRIALS CAST CAST II AFFIRM RACE RACE-II PIAF STAF HOT-CAFE AF-CHF
46 Many agents lack favorable data Meta-analysis of quinidine therapy 6 randomized controlled trials reviewed (1980s) Quinidine vs placebo after cardioversion At 12 months: 50 % quinidine groups in SR 25% of control groups in SR Total mortality rate: Quinidine 2.9 % vs Control 0.8% (p<0.05) Quinidine effective at rhythm control but 3x more lethal Coplen SE et al. Circulation Oct;82(4):
47 AFFIRM Trial Largest, most pivotal AF trial to date n = 4060 (at 213 clinical sites) Intention to treat (ITT design) Baseline characteristics of patients Age 65 years No contraindications to anticoagulation or a rate or rhythm drug Other risk factors for stroke/death New AF patients randomized to receive Long-term rate control CCB, BB, or digoxin (chosen by treating physician to control resting HR 80 or 110 after 6 min walk ) Warfarin mandated Long-term rhythm control Oral Class I/III drugs (chosen by treating physician) most common amiodarone > sotalol > propafenone, procainamide N Eng J Med 2002;347:
48 AFFIRM Results Cumulative Mortality from Any Cause No significant difference in mortality Rhythm group: Trend towards increased mortality N Eng J Med 2002;347:
49 AFFIRM Trial Considerations Rate control not worse that rhythm control overall Possibly superior in: Elderly CAD no CHF Rhythm group: Higher % of TdP, cardiac arrest, hospitalization (p = 0.01) Higher % of drug-related side effects ( p<0.05) 62% maintained in sinus rhythm at 5 years Incidence of stroke similar in each group Limitations Multiple rate/rhythm drugs could be used in each group Selection bias Only applicable for age > 65 N Eng J Med 2002;347:
50 Other Landmark Trials RACE, PIAF, STAF, HOT-CAFE All consistent with results of AFFIRM Not applicable to HF patients AF-CHF trial (2008) AF patients with LVEF < 35% and HF symptoms Results: No advantage with rhythm control in HF AF-CHF: N Engl J Med 2008;358:
51 Where are we now? It is acceptable to leave patients in AF and only control rate Rate vs rhythm Comparable mortality and stroke [AFFIRM] Class I drugs used in extreme caution post-mi (i.e. any SHD) [CAST Trial 1991]
52 So when DO we pursue a long-term rhythm strategy? (convert & keep in SR) When: Symptomatic patients despite rate control Unable to achieve HR 110 Younger patients or patients who prefer no long-term anticoagulation Pill-in-the-Pocket Patients who have had a safety trial of propafenone or flecainide can utilize a single-dose approach outpatient upon AF onset (IIa LOE B) Recent-onset AF, no drugcontraindications AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76
53 Preferred long-term rhythm control strategies Heart Failure Coronary Artery Disease only 1. amiodarone or dofetilide No SHD 1. sotalol or dofetilide or dronedarone (smaller subset of population) propafenone or flecainide or sotolol Hypertrophic cardiomyopathy Class Ia disopyramide! Amiodarone vs Sotalol two most-prescribed anti-arrhythmics Amiodarone: better at maintaining SR, good in HF, more widely prescribed, but more toxic Sotalol: AS effective in CAD, less side effects, but renally eliminated, (?advanced age) Both have AV nodal properties, limiting need for rate control (?) Above anti-arrhythmics ~50% at maintaining SR at 1 year (except amiodarone = %) SHD CAD, s/p MI, valve disease, LV dysfunction/lvh Therapy Vole 7; 4 p. 391 AFFIRM Investigators. N Eng J Med 2002;347:
54 2014 AHA/ACC AF Guidelines (for rhythm control)
55 There exist no one perfect anti-arrhythmic drug Benefit of maintaining SR Side effects of anti-arrhythmic drug Balance varies based on Patient factors Drug
56 Cathater ablation (see picture on next slide) What Radio-frequency ablation Cryo-ablation ( freezing ) How After reentry spot is located, high-frequency radiowaves burn a small area of tissue rendering it inactive. Difficult in AF many re-entrant pathways exist Post-care and recurrence of AF 20-50% recurrence at one year Majority within 3 months AAD added/continued for 3 months to reduce recurrence Higher success rate with multiple ablations Ganesan AN, J Am Heart Assoc Apr;2(2):e
57
58 Catheter ablation Atrial Flutter First line therapy 90% effective (because.one re-entrant focus) AF Class I recommendation: Symptomatic paroxysmal AF Class II recommendation Afib refractory to medication Not able to tolerate AAD non-compliant w/ AAD Can be chosen as first line rhythm control method over AAD Advantages: avoid long-term use of AAD Risks thromboembolic events, cardiac tamponade, pulmonary vein stenosis (4.5% of patients) AHA/ACC/HRS Atrial Fibrillation Guideline. JACC 2014;64(21):e1-e76 Spector P, et al. Am J Cardiol 2009;104:
59 Treating AF Summary Class I agents are of little benefit in most patients Other anti-arrhythmics are falling out of favor also Its OK to leave patients in AF and just control rate! AFFIRM Trial No perfect anti-arrhythmic agent Toxic, pro-arrhythmic, and patient dependent! Newer non-pharmacological strategies emerging Catheter ablation
60 QUESTIONS? There are NO stupid questions..just stupid answers
61 Heart Block (AV block) AV node blocked in varying degrees speed bump (1 st degree) lane-change/detour (2 nd degree) road block (3 rd degree) Life-threatening severity Heart-Block ECG Tip: Focus on PR interval 1 st deg: long P-R interval (common and rarely symptomatic 2 nd deg (can be vaguely referred to as 2:1 block) Type I: progressively longer and longer P-R until QRS dropped Type II: regular P-R, then occasional dropped QRS 3 rd deg (P waves and QRS completely independent) i.e. P wave does not cause QRS i.e. no communication from atria to ventricle (inherent ventricular rate = HR = 40 bpm)
62 Treatment 1 st degree heart block usually incidental finding and asymptomatic 2 nd and 3 rd degree heart block Immediate: atropine and catecholamines (i.e. isoproterenol) Tanscutaneous pacing (temporary pacing) Remove AV node blocking agenst B-Blockers and non-dhp CCB contraindicated in heart-block Ventricular pacemaker necessary in 2 nd /3 rd degree
NO SKIPPED BEATZ: A PRACTICAL REVIEW OF THE ANTI-ARRHYTHMIX. feat. Lance Ray, Pharm.D., BCPS
NO SKIPPED BEATZ: A PRACTICAL REVIEW OF THE ANTI-ARRHYTHMIX feat. Lance Ray, Pharm.D., BCPS Learning Objectives No Skipped Beatz: A Practical Review of Anti-arrhythmix Get Rhythm: The Anti-arrhythmic Remix
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationChapter 26. Media Directory. Dysrhythmias. Diagnosis/Treatment of Dysrhythmias. Frequency in Population Difficult to Predict
Chapter 26 Drugs for Dysrythmias Slide 33 Slide 35 Media Directory Propranolol Animation Amiodarone Animation Upper Saddle River, New Jersey 07458 All rights reserved. Dysrhythmias Abnormalities of electrical
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAntiarrhythmic Drugs 1/31/2018 1
Antiarrhythmic Drugs 1/31/2018 1 Normal conduction pathway: 1- SA node generates action potential and delivers it to the atria and the AV node 2- The AV node delivers the impulse to purkinje fibers Other
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationAtrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences
Depolarization & ECG Atrial Fibrillation How to make ORDER out of CHAOS Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Depolarization & ECG Depolarization & ECG Atrial Fibrillation Hemodynamic Consequences
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationDECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical
DECLARATION OF CONFLICT OF INTEREST Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical ESC Congress Paris, France August 27-31, 2011 Risk & Complications of AADs for Rhythm
More informationCVD: Cardiac Arrhythmias. 1. Final Cardiac Arrhythmias_BMP. 1.1 Cardiovascular Disease. Notes:
CVD: Cardiac Arrhythmias 1. Final Cardiac Arrhythmias_BMP 1.1 Cardiovascular Disease 1.2 Directions for taking this course 1.3 Content Experts 1.4 Disclosures 1.5 Accreditation Information 1.6 Learning
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationThe most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension
Arrhythmias in the critically ill ICU patients: Approach for rapid recognition & management Objectives Be able to identify and manage: Atrial fibrillation with a rapid ventricular response Atrial flutter
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationEtienne Aliot. University of Nancy - France
Etienne Aliot University of Nancy - France Disclosures Consulting fees : - Bayer, Boehringer Ingelheim,GSK, MedaPharma, Pfizer/BMS,Sanofi Aventis. - Biotronik,Medtronic,St Jude Medical. Electrical vs Pharmacological
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationHow do arrhythmias occur?
How do arrhythmias occur? An arrhythmia is an abnormal heart rhythm (= dysrhythmia). Can be fast (tachy) or slow (brady). Brady arrhythmias are usually due to conduc;on block, while tachyarrhythmias are
More informationANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar
ANTI-ARRHYTHMICS AND WARFARIN Dr Nithish Jayakumar Contents 1. Anti-arrhythmics Pacemaker and myocardial potentials Drug classes mechanisms; s/e; contra-indications Management of common arrhythmias 2.
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationAnti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University
Anti arrhythmic drugs Hilal Al Saffar College of medicine Baghdad University Mechanism of Arrhythmia Abnormal heart pulse formation Abnormal heart pulse conduction Classification of Arrhythmia Abnormal
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationAPPROACH TO TACHYARRYTHMIAS
APPROACH TO TACHYARRYTHMIAS PROF.DR.MD.ZAKIR HOSSAIN PROFESSOR AND HEAD DEPARTMENT OF MEDICINE SZMCH TACHYARRYTHMIA Cardiac arrythmia is a disturbance of electrical rhythm of heart. Cardac arrythmia with
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationAlaska Nurse Practitioner Annual Conference 2009
Alaska Nurse Practitioner Annual Conference 2009 LAURIE RACENET, RN, MSN, ANP, CEPS, CCDS Alaska Heart Institute Member: Boston Scientific Allied Professional Advisory Board Participant in Industry Sponsored
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationI have nothing to disclose.
I have nothing to disclose. Antiarrhythmic Therapy in Pregnancy Prof. Ali Oto,MD,FESC,FACC,FHRS Department of Cardiology Hacettepe University,Faculty of Medicine Ankara Arrhythmias in pregnancy An increased
More informationArrhythmias (I) Supraventricular Tachycardias. Disclosures
Arrhythmias (I) Supraventricular Tachycardias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Short R-P Tachycardia REGULAR with 1:1 P/R relationship
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationAntiarrhythmic Pharmacology. The Electronics
Antiarrhythmic Pharmacology Linking Pharmacological Treatment to the Patient and the Rhythm Presented By: Karen Marzlin BSN, RN,C, CCRN-CMC CNEA 2009 1 The Electronics Action Potential of Cardiac Cells
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationArrhythmic Complications of MI. Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine
Arrhythmic Complications of MI Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine Objectives Brief overview -Pathophysiology of Arrhythmia ECG review of typical
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationAtrial fibrillation in the ICU
Atrial fibrillation in the ICU Atrial fibrillation Preexisting or incident (new onset) among nearly one in three critically ill patients Formation of arrhythogenic substrate usually fibrosis (CHF, hypertension,
More informationCSI Skills Lab #5: Arrhythmia Interpretation and Treatment
CSI 202 - Skills Lab #5: Arrhythmia Interpretation and Treatment Origins of the ACLS Approach: CSI 202 - Skills Lab 5 Notes ACLS training originated in Nebraska in the early 1970 s. Its purpose was to
More informationSHOCK THE PATIENT. Disclosures. Goals of the Talk. Tachyarrhythmias- Unstable 11/7/2017
Disclosures Common Heart Rhythms in the Hospital Research Support: NIH, PCORI, Medtronic, Cardiogram Consulting: InCarda, Johnson & Johnson, Lifewatch Equity: InCarda Gregory M Marcus, MD, MAS Associate
More informationAcute Arrhythmias in the Hospitalized Patient
Acute Arrhythmias in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisc Disclosures Medtronic: Research Support
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationECGs and Arrhythmias: Family Medicine Board Review 2012
Overview ECGs and Arrhythmias: Family Medicine Board Review 2012 Jess Waldura, MD University of California, San Francisco walduraj@nccc.ucsf.edu Bundle branch blocks Quick review of ischemia Arrhythmias
More informationAmiodarone Prescribing and Monitoring: Back to the Future
Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran
More informationArrhythmia 341. Ahmad Hersi Professor of Cardiology KSU
Arrhythmia 341 Ahmad Hersi Professor of Cardiology KSU Objectives Epidemiology and Mechanisms of AF Evaluation of AF patients Classification of AF Treatment and Risk stratification of AF Identify other
More informationCardiac Arrhythmias. For Pharmacists
Cardiac Arrhythmias For Pharmacists Agenda Overview of the normal Classification Management Therapy Conclusion Cardiac arrhythmias Overview of the normal Arrhythmia: definition From the Greek a-, loss
More informationCore Content In Urgent Care Medicine
Palpitations/Arrhythmias Ebrahim Barkoudah, MD Clinical Instructor in Internal Medicine Harvard Medical School Assistant in Internal Medicine & Pediatrics Massachusetts General Hospital MGH Chelsea Chelsea,
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationArrhythmias. 1. beat too slowly (sinus bradycardia). Like in heart block
Arrhythmias It is a simple-dysfunction caused by abnormalities in impulse formation and conduction in the myocardium. The heart is designed in such a way that allows it to generate from the SA node electrical
More informationPediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division
Pediatrics ECG Monitoring Pediatric Intensive Care Unit Emergency Division 1 Conditions Leading to Pediatric Cardiology Consultation 12.7% of annual consultation Is arrhythmias problems Geggel. Pediatrics.
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationTreatment of Arrhythmias in the Emergency Setting
Treatment of Arrhythmias in the Emergency Setting Zian H. Tseng, M.D. Assistant Professor of Medicine Cardiac Electrophysiology Section Cardiology Division University of California, San Francisco There
More informationChapter 16: Arrhythmias and Conduction Disturbances
Complete the following. Chapter 16: Arrhythmias and Conduction Disturbances 1. Cardiac arrhythmias result from abnormal impulse, abnormal impulse, or both mechanisms together. 2. is the ability of certain
More information1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material
1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material Arrhythmia recognition This tutorial builds on the ECG lecture and provides a framework for approaching any ECG to allow the
More informationAntiarrhythmic agents in 2014
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Antiarrhythmic agents in 2014 Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice, Italy
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationAblation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group
Ablation Update and Case Studies Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group Disclosures No financial relationships to disclose Objectives At the conclusion of this activity,
More informationChapter 14. Agents used in Cardiac Arrhythmias
Chapter 14 Agents used in Cardiac Arrhythmias Cardiac arrhythmia Approximately 50% of post-myocardial infarction fatalities result from ventricular tachycarida (VT) or ventricular fibrillation (VF). These
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationDysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias
Dysrhythmias Dysrythmias & Anti-Dysrhythmics Rhythm bad in the heart: Whitewater rafting Electrical impulses coordinate heart Reduction in Cardiac Output PEA Asystole Components of an ECG Wave EKG Parameters
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationPATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE. Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology
PATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology Medical University of Łódź The heart is made up of four chambers Left Atrium Right Atrium Left Ventricle
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
More informationArrhythmia Management Joshua M. Cooper, MD, FHRS, FACC
Arrhythmia Management Joshua M. Cooper, MD, FHRS, FACC Professor of Medicine Director of Cardiac Electrophysiology Temple University Health System Plumbing Electrical System Bradyarrhythmias Sinus Node
More informationECGs and Arrhythmias: Family Medicine Board Review 2009
Rate Rhythm Intervals Hypertrophy ECGs and Arrhythmias: Family Medicine Board Review 2009 Axis Jess (Fogler) Waldura, MD University of California, San Francisco walduraj@nccc.ucsf.edu Ischemia Overview
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More information03/27/2014. Suzanne M. Lifer: Nothing to disclose Michelle R. Musser: Nothing to disclose
Suzanne Lifer, PharmD Michelle Musser, PharmD, BCPS Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may
More informationCatheter Ablation for AF: Patients, Procedures, Outcomes
Catheter Ablation for AF: Patients, Procedures, Outcomes John Sapp Director Heart Rhythm, QEII Health Sciences Centre Professor of Medicine, Dalhousie University Atrial Fibrillation Atrial Fibrillation
More informationARRHYTHMIA SINUS RHYTHM
ARRHYTHMIA Dr. Ahmed A. Elberry, MBBCH, MSc, MD Assistant Professor of Clinical Pharmacy Faculty of pharmacy, KAU 1 SINUS RHYTHM SA node is cardiac pacemaker Normal sinus rhythm 60-100 beats/min Depolarisation
More informationPediatrics. Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment. Overview
Pediatrics Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment See online here The most common form of cardiac arrhythmia in children is sinus tachycardia which can be caused by
More informationRate Control versus Rhythm Control in NSTEMI
Rate Control versus Rhythm Control in NSTEMI Gulmira Kudaiberdieva, MD, FESC Adana, Turkey Conflict of interest: None to declare Istanbul - 2012 OUTLINE Significance of AF in ACS Prognostic value of AF
More informationManagement strategies for atrial fibrillation Thursday, 20 October :27
ALTHOUGH anyone who has had to run up a flight of steps or has had a frightening experience is quite familiar with a racing heartbeat, for the more than 2 million Americans who suffer from atrial fibrillation
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationAtrial Fibrillation: Beyond the AFFIRM trial
Atrial Fibrillation: Beyond the AFFIRM trial Daniel J. Cantillon MD FACC FHRS Cardiac Electrophysiology and Pacing Assistant Professor, Lerner College of Medicine Cleveland Clinic, Heart & Vascular Institute
More information2) Heart Arrhythmias 2 - Dr. Abdullah Sharif
2) Heart Arrhythmias 2 - Dr. Abdullah Sharif Rhythms from the Sinus Node Sinus Tachycardia: HR > 100 b/m Causes: o Withdrawal of vagal tone & Sympathetic stimulation (exercise, fight or flight) o Fever
More informationManagement of acute Cardiac Arrhythmias
Management of acute Cardiac Arrhythmias Dr. Zulkeflee Muhammad MBChB (New Zealand), MRCP (United Kingdom) Cardiologist Electrophysiology Unit Istitut Jantung Negara Objectives Review the etiology and recognition
More informationAntiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiarrhythmic Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 2 Ion Permeability Changes Potential Changes Genes and Proteins 3 Cardiac Na+ channels 5 6
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationAtrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist
Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,
More informationInitial Evaluation and Early Stabilization: Best Practices for the AF Patient Wayne Ruppert, CVT, CCCC, NREMT-P
Initial Evaluation and Early Stabilization: Best Practices for the AF Patient Wayne Ruppert, CVT, CCCC, NREMT-P Cardiovascular Coordinator Bayfront Health Dade City This presentation is available for download
More informationAtrial Fibrillation: It s More than a Rhythm
Atrial Fibrillation: It s More than a Rhythm Relax and Learn at the Farm 2013 DNP, RN, CCNS, CCRN-CMC, CHFN Cardiovascular Nursing Education Associates 1 The Quality of a Person s Life is Directly Proportional
More informationArrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family of disorders that show variety of symptoms, for
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationReview Packet EKG Competency This packet is a review of the information you will need to know for the proctored EKG competency test.
Review Packet EKG Competency 2015 This packet is a review of the information you will need to know for the proctored EKG competency test. Normal Sinus Rhythm Rhythm: Regular Ventricular Rate: 60-100 bpm
More informationDon t Forget the Basics
Scary Arrhythmias in the Hospital Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisc Don t Forget the Basics 79 yo man with a history
More information